Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 198 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: chloroquine phosphate Clear all
Terminated Phase 1 Interventional Results available

Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01026844
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
erlotinib, hydroxychloroquine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 12, 2026, 9:30 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)

NCT04318444
View directory record Official record
Conditions
COVID-19, Corona Virus Infection
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 12, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00714181
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
hydroxychloroquine, temozolomide, TdT-mediated dUTP nick end labeling assay, western blotting, electron microscopy, high performance liquid chromatography, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, pharmacological study
Drug · Genetic · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Sep 12, 2026, 9:30 PM EDT
Terminated Phase 1 Interventional

Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia

NCT02631252
View directory record Official record
Conditions
Leukemia, Acute Myelogenous
Interventions
Hydroxychloroquine, Mitoxantrone, Etoposide
Drug
Lead sponsor
Alison Sehgal, MD, MS
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 12, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer

NCT02316340
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Vorinostat, Hydroxychloroquine, Regorafenib
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 12, 2026, 9:30 PM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus

NCT03428945
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
37
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 12, 2026, 9:30 PM EDT
Terminated Phase 2 Interventional Results available

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

NCT04527549
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration, Trametinib dimethyl sulfoxide
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
199
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 139 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 12, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis

NCT00579878
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate-Sulfasalazine-Hydroxychloroquine, Leflunomide-Sulfasalazine-Hydroxychloroquine
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 12, 2026, 9:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer

NCT02124681
View directory record Official record
Conditions
Insulin Resistance
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 69 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 12, 2026, 9:30 PM EDT
Terminated Phase 2 Interventional Results available

Treating COVID-19 With Hydroxychloroquine (TEACH)

NCT04369742
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine (HCQ), Placebo: Calcium citrate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 12, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT

NCT03283566
View directory record Official record
Conditions
Chronic Pancreatitis, Insulin Dependent Diabetes
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 12, 2026, 9:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CiPA Phase 1 ECG Biomarker Validation Study

NCT03070470
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 12, 2026, 9:30 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)

NCT04363450
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, Wuhan Coronavirus, Prophylaxis, Healthcare Worker, Sars-CoV2, Hydroxychloroquine
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Lafayette, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 12, 2026, 9:30 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")

NCT03400254
View directory record Official record
Conditions
Breast Cancer
Interventions
Hydroxychloroquine (HCQ), Gedatolisib
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Sep 12, 2026, 9:30 PM EDT
Terminated Phase 1 Interventional

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy

NCT02414776
View directory record Official record
Conditions
Estrogen Receptor Positive Breast Cancer
Interventions
hydroxychloroquine
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 12, 2026, 9:30 PM EDT
Terminated Phase 3 Interventional

Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)

NCT04421664
View directory record Official record
Conditions
Corona Virus Infection, SARS-CoV Infection, Coronavirus
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 12, 2026, 9:30 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

NCT04328961
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
Interventions
Hydroxychloroquine Sulfate, Ascorbic Acid
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
8
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 12, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

NCT04335084
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection, COVID, Coronavirus, Coronavirus-19, Coronavirus 19
Interventions
Hydroxychloroquine, Vitamin C, Vitamin D, Zinc
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 12, 2026, 9:30 PM EDT
Withdrawn Phase 2 Interventional

Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss

NCT02379650
View directory record Official record
Conditions
Recurrent Pregnancy Loss, Miscarriage
Interventions
Hydroxychloroquine (HCQ), Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Sep 12, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

NCT00726596
View directory record Official record
Conditions
Prostate Cancer
Interventions
hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
5
States / cities
Hamilton, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Sep 12, 2026, 9:30 PM EDT
Recruiting Phase 2 Interventional

Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

NCT02932007
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Chloroquine Phosphate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 12, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment

NCT00909831
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
hydroxychloroquine, temsirolimus, electron microscopy, high performance liquid chromatography, immunologic technique, laboratory biomarker analysis, mass spectrometry, pharmacological study, autophagy inhibition therapy
Drug · Other · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 12, 2026, 9:30 PM EDT
Terminated Phase 1 Interventional

Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma

NCT01144169
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Hydroxychloroquine (HC)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
19 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 12, 2026, 9:30 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Trial of Hydroxychloroquine In Covid-19 Kinetics

NCT04353271
View directory record Official record
Conditions
Covid 19, Corona Virus Infection
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of South Alabama
Other
Eligibility
19 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Sep 12, 2026, 9:30 PM EDT